Tel : +33 (0) 4.38.02.36.50
contact@promise-proteomics.com
www.promise-proteomics.com

Product name	INFLIXIMAB Labelled standard
Catalog number	REX08151

Product description

Labelled Infliximab is a recombinant, stable isotope labelled, chimeric monoclonal antibody designed for use as an internal standard for quantitative analysis of Infliximab in plasma samples. Infliximab is a human TNF-α blocker that is used for the treatment of autoimmune diseases, such as Crohn's disease and arthritis.

Similar products: Labelled Adalimumab, Labelled Etanercept, Labelled Rituximab

mAb sequence

Heavy chain

EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTE
DTGVYYCSRNYYGSTYDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Light Chain

DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWP
FTFGSGTNLEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEK
HKVYACEVTHQGLSSPVTKSFNRGEC

Product features and protocols

Key features

1	Purity	>95% as determined by SDS-PAGE
2	Labelling	Arg-$^{13}C_6$,$^{15}N_4$ | Lys-$^{13}C_6$,$^{15}N_2$
3	Isotopic incorporation	>99% as determined by LC-MS/MS analysis of digested SIL-mAb

Other features

Expression System	Mammalian cells
Protein content	Quantitation is carried out by UV Absorbance at 280 nm
Formulation	Lyophilized from buffer: 20 mM Sodium Phosphate pH7.2; 5% Sucrose; 0.005% Polysorbate 80.

Product preparation

For product preparation we recommend the following steps:

1. Briefly centrifuge the tube before opening
2. Reconstitute by adding the appropriate volume of ultrapure water for a final concentration of 200 µg/ml (e.g. 50 µl for 10 µg or 250 µl for 50 µg)
3. Vortex gently to insure complete dissolution
4. Wait 15 minutes at room temperature before proceeding further
5. Vortex gently again and centrifuge briefly

Product storage

The product is lyophilized and shipped at ambient temperature. **Store at -80 °C upon receipt.**
After reconstitution, the protein can be preserved at 4°C for a few weeks.

Avoid multiple freeze-thaw cycles

PROMISE Proteomics SAS, BHT 52A 7, parvis Louis Néel – CS20050
38040 Grenoble Cedex 9 – France

Tel : +33 (0) 4.38.02.36.50
contact@promise-proteomics.com
www.promise-proteomics.com

How to use our product

SIL mAbs are used as an internal standards by addition at the start of a sample preparation workflow. Both Labelled and target therapeutic mAbs will be processed throughout the entire analytical procedure controlling for variability caused by pre-analytical treatments or incomplete enzymatic digestion (1).

Supporting information



SDS-PAGE gel analysis of INFLIXIMAB protein in non-reducing/ non heated conditions (NR/NH)
Stained with Coomassie blue

References

1. **D. Lebert, G.Picard, et al.** Absolute and multiplex quantification of antibodies in serum using PSAQ™ standards and LC-MS/MS, Bioanalysis. 2015, 7, 1237-51.
2. **J. Jourdil, D. Lebert, et al.** Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods? Anal. Bioanal. Chem. 2017, 409, 1195-1205.
3. **J. Jourdil, F. Stanke-Labesque, et al.** Simultaneous quantification of adalimumab and infliximab in human plasma by liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring. 2018, 40, 417-424.
4. **M. El Amrani, E. Maarseveen, et al.** Simultaneous quantification of free adalimumab and infliximab in human plasma using a target-based sample purification and liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring. 2019, 41, 640-647.

The product is intended for research use only. Not for diagnostic or therapeutic use.

Legal

PROMISE Proteomics SAS, BHT 52A 7, parvis Louis Néel – CS20050
38040 Grenoble Cedex 9 – France

PROMISE Proteomics SAS
7 parvis Louis Néel, BHT52A, CS20050, 38040 Grenoble FRANCE
Email: contact@promise-proteomics.com

SAFETY DATASHEET

Version: 2
Revision Date: 25SEP2019

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

Product Name: Recombinant Inflximab monoclonal antibody
Product Number: REX08151

Relevant identified uses of the substance or mixture and uses advised against

This product is for research use only.
This product is not intended for therapeutic use. It should not be administered to humans or animals.

Details of the supplier of the safety data sheet

PROMISE Proteomics SAS
7 parvis Louis Néel, CS20050, Bat52A
38040 Grenoble
FRANCE:
Tel: +33.4.38.02.36.50
Fax: +33.4.38.02.10.38
Email: contact@promise-proteomics.com

Emergency telephone number: +0033.4.38.02.36.50 (8.00am-17.00pm)
Email: reactovigilance@promise-proteomics.com

2. HAZARDS IDENTIFICATION

Classification of the substance

Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.

Label elements

Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.

Other information

None

3. COMPOSITION/INFORMATION OF INGREDIENTS

No components need to be disclosed according to the applicable regulations.

4. FIRST AID MEASURES

Description of first aid measures

- Eye contact: Immediately flush with plenty of water. After initial flushing, remove any contact lenses and continue flushing for at least 15 minutes.
- Skin contact: Wash off immediately with soap and plenty of water while removing all contaminated clothes and shoes.
- Ingestion: Clean mouth with water. Drink plenty of water.
- Inhalation: Move to fresh air.

Most important symptoms and effects, both acute and delayed

No information available

PROMISE Proteomics SAS
7 parvis Louis Néel, BHT52A, CS20050, 38040 Grenoble FRANCE
Email: contact@promise-proteomics.com

Indication of any immediate medical attention and special treatment needed
Treat symptomatically

5. FIRE-FIGHTING MEASURES
Extinguishing media
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special hazards arising from the substance or mixture
None in particular.

Advice for fire-fighters
Special protective equipment for fire-fighters As in any fire, wear self-contained breathing apparatus and full protective gear.

6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Ensure adequate ventilation.

Environmental precautions
Prevent further leakage or spillage if safe to do so.

Methods and materials for containment and cleaning up
Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust).

7. HANDLING AND STORAGE
Precautions of safe handling
Ensure adequate ventilation.

Conditions of safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.

Specific end uses
No information available.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters:
Exposure limits: National occupational exposure limits
Derived No Effect Level: No information available
Predicted No Effect Concentration: No information available

Exposure controls:
Engineering measures Ensure adequate ventilation, especially in confined areas.
Personal protective equipment
Eye protection Tightly fitting safety goggles.
Hand protection Protective gloves.
Skin and body protection Long sleeved clothing.
Respiratory protection No special protective equipment required.
Thermal hazards No information available

Hygiene measures:

PROMISE Proteomics SAS
7 parvis Louis Néel, BHT52A, CS20050, 38040 Grenoble FRANCE
Email: contact@promise-proteomics.com

Handle in accordance with good industrial hygiene and safety practice.

Environmental exposure controls : No information available.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical State @20°C: No information available
Odor: No information available
Appearance: no information available

pH: No information available
Melting/freezing point: No information available
Boiling point/boiling range: No information available
Flash point: No information available
Evaporation rate: No information available
Flammability (solid,gas): No information available
Vapor pressure: No information available
Vapor density: No information available
Relative density: No information available
Water solubility: No information available
Solubility in other solvents: No information available
Partition coefficient : n-octanol/water: No information available
Autoignition temperature: No information available
Decomposition temperature: No information available
Viscosity, kinematic: No information available
Explosive properties: No information available

VOC content (%): No information available

10. STABILITY AND REACTIVITY

Reactivity: No information available
Chemical stability: Stable under normal conditions
Precautional Statements: None under normal processing
Conditions to avoid: Heat, flames and sparks.
Incompatible materials: None in particular
Hazardous decomposition products: None under normal conditions.

11. TOXICOLOGICAL INFORMATION

Information on toxicological effects

Product information: No data available
Inhalation: No data available
Eye contact: No data available
Skin contact: No data available
Ingestion: No data available

Chronic toxicity

Corrositivity: No information available
Sensitization: No information available
Neurological effects: No information available
Reproductive toxicity: No information available
Mutagenic effects: No information available
Target Organ effects: No information available

12. ECOLOGICAL INFORMATION

Toxicity: As supplied, the preparation is not expected to present significant adverse environmental effects.
Persistence and degradability: No information available

PROMISE Proteomics SAS
7 parvis Louis Néel, BHT52A, CS20050, 38040 Grenoble FRANCE
Email: contact@promise-proteomics.com

Bioaccumulative potential: No information available
Mobility in soil: No information available
Results of PBT and vPvB assessment: No information available
Other adverse effects: No information available

13. DISPOSAL CONSIDERATIONS

Waste from residues/unused products: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.

14. TRANSPORT INFORMATION

Not dangerous goods

15. REGULATORY INFORMATION

This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006

16. OTHER INFORMATION

Disclaimer:
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty of quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or any in process, unless specified in the text.